NOVEL INTEGRIN alpha9 beta1 LIGAND AND USES THEREOF
AssigneeOsaka University
InventorsKiyotoshi Sekiguchi, Ryoko Sato, Sachiko Ezoe
Life of this patent
Estimating the term…
Abstract
Provided is a novel ligand for integrin α9β1 consisting of a peptide having the following amino acid sequence: (A) EDDMMEVPY (SEQ ID NO: 1) or (B) an amino acid sequence the same as the amino acid sequence represented by SEQ ID NO: 1 except for having deletion, substitution or addition of 1 to 3 amino acids. The novel ligand for integrin α9β1 has a higher binding affinity than those of tenascin-C and osteodontin, which are known ligands for integrin α9β1.
Claims16
1-12. (canceled)
A ligand for integrin α9β1, consisting of a peptide having the following amino acid sequence:
- (A) EDDMMEVPY (SEQ ID NO:
- 1) or
- (B) an amino acid sequence the same as the amino acid sequence represented by SEQ ID NO:
- 1 except for having deletion, substitution or addition of 1 to 3 amino acids.
A ligand for integrin α9β1 consisting of the following peptide:
- (a) a peptide consisting of EDDMMEVPY (SEQ ID NO:
- 1),
- (b) a peptide the same as peptide (a) except that E at residue 1;
- E at residue 1 and D at residue 2;
- Y at residue 9;
- E at residue 1 and Y at residue 9;
- or E at residue 1, D at residue 2 and Y at residue 9 are deleted or substituted by an amino acid(s);
- or
- (c) a peptide the same as peptide (a) or (b) except that M at residue 4, V at residue 7, or P at residue 8 is substituted by an amino acid.
A fragment of SVEP1 comprising the following peptide:
- (a) a peptide consisting of EDDMMEVPY (SEQ ID NO:
- 1),
- (b) a peptide the same as peptide (a) except that E at residue 1;
- E at residue 1 and D at residue 2;
- Y at residue 9;
- E at residue 1 and Y at residue 9;
- or E at residue 1, D at residue 2 and Y at residue 9 are deleted or substituted by an amino acid(s);
- or
- (c) a peptide the same as peptide (a) or (b) except that M at residue 4, V at residue 7, or P at residue 8 is substituted by an amino acid,
- the fragment having 2500 amino acid residues or less and an integrin-α9β1 binding activity.
Dependencies are inferred from the claim text.